All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On behalf of the International Waldenstrom's Macroglobulinemia Foundation (IWMF), the Lymphoma Hub was pleased to speak with Stephen Ansell, Mayo Clinic, Rochester, US, who chaired a discussion on, What are the novel treatment options for patients with relapsed or refractory Waldenstrom's Macroglobulinemia (WM)? This discussion also featured Christian Buske, Monique Minnema, Sheeba Koshy Thomas, and Jorge J. Castillo.
What are the novel treatment options for patients with relapsed or refractory WM?
Buske begins by explaining how chemotherapy-free approaches could be the future of WM treatment and highlights the important role of Bruton’s tyrosine kinase inhibitors. The current structure of clinical trials is discussed, focusing on what patients would want regarding effectiveness, duration of the trial, and limiting exposure to side effects. The panel describes the possible use of immunotherapy vaccines, though these are limited due to burden of disease where they might not be as effective. Finally, Castillo discusses the potential of Bruton’s tyrosine kinase inhibitions, in combination with targeted agents, such as BCL-2 inhibitors, as well as the use of antibody conjugates in the future treatment of WM.
'The International Waldenstrom's Macroglobulinemia Foundation (IWMF) and the Lymphoma Hub are working in collaboration for patients with Waldenstrom's macroglobulinemia. This initiative aims to increase awareness of Waldenstrom's macroglobulinemia among healthcare professionals, patients, caregivers, and the patient advocacy community.
This initiative is funded by Cellectar Biosciences, BeiGene and Eli Lilly. All content is developed independently by SES in collaboration with an expert steering committee; funders are allowed no direct influence on the content of the hub.’
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox